C4 Therapeutics reported a quarterly loss of $0.20 per share, slightly better than the Zacks Consensus Estimate of a $0.21 loss and improved from a $0.37 loss a year ago. The small earnings beat and year-over-year loss improvement are modestly supportive, but the update contains no revenue or guidance details. The news is likely to have limited near-term share-price impact.
C4 Therapeutics reported a quarterly loss of $0.20 per share, slightly better than the Zacks Consensus Estimate of a $0.21 loss and improved from a $0.37 loss a year ago. The small earnings beat and year-over-year loss improvement are modestly supportive, but the update contains no revenue or guidance details. The news is likely to have limited near-term share-price impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.18
Ticker Sentiment
